TABLE 4.
BTKO threshold | Prandial state | 25 mg | 50 mg | 75 mg | 100 mg | 200 mg |
---|---|---|---|---|---|---|
Simulated % of participants | ||||||
q.d. dosing regimen | ||||||
0.70 | Fasted | 98 | 100 | 100 | 100 | 100 |
0.80 | 88 | 97 | 99 | 99 | 100 | |
0.90 | 36 | 59 | 71 | 77 | 87 | |
0.95 | 4 | 13 | 20 | 24 | 39 | |
0.70 | Fed | 99 | 100 | 100 | 100 | 100 |
0.80 | 95 | 99 | 99 | 99 | 100 | |
0.90 | 54 | 74 | 82 | 85 | 92 | |
0.95 | 10 | 22 | 29 | 34 | 51 | |
b.i.d. dosing regimen | ||||||
0.70 | Fasted | 100 | 100 | 100 | 100 | 100 |
0.80 | 99 | 100 | 100 | 100 | 100 | |
0.90 | 88 | 97 | 99 | 100 | 100 | |
0.95 | 38 | 68 | 81 | 86 | 94 | |
0.70 | Fed | 100 | 100 | 100 | 100 | 100 |
0.80 | 100 | 100 | 100 | 100 | 100 | |
0.90 | 96 | 99 | 100 | 100 | 100 | |
0.95 | 59 | 85 | 90 | 93 | 97 |
Abbreviations: b.i.d., twice‐daily; BTKO, Bruton's tyrosine kinase occupancy; q.d., once‐daily.